MedTrace Logo

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

NCT06011330 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2023-08-30

No results posted yet for this study

Summary

The survival of the refractory CRC is dismal and therapy options are limited ，the researchers aim to investigate the efficacy, safety, and predictors of fruquintinib plus PD-1 in refractory MSS metastatic colorectal cancer in a real-world setting.

Conditions

Interventions

DRUG

Fruquintinib combined with anti-PD-1 antibodies

Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).

Sponsors & Collaborators

  • Hunan Cancer Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2022-06-30
Completion
2023-02-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06011330 on ClinicalTrials.gov